NO983372L - Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter - Google Patents

Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter

Info

Publication number
NO983372L
NO983372L NO983372A NO983372A NO983372L NO 983372 L NO983372 L NO 983372L NO 983372 A NO983372 A NO 983372A NO 983372 A NO983372 A NO 983372A NO 983372 L NO983372 L NO 983372L
Authority
NO
Norway
Prior art keywords
ribavirin
activated
lymphocytes
modulation
analogs
Prior art date
Application number
NO983372A
Other languages
English (en)
Norwegian (no)
Other versions
NO983372D0 (no
Inventor
Robert Tam
Kandsamy Ramasamy
Devron Averett
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO983372(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of NO983372D0 publication Critical patent/NO983372D0/no
Publication of NO983372L publication Critical patent/NO983372L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
NO983372A 1996-01-23 1998-07-22 Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter NO983372L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P 1997-01-17 1997-01-17
PCT/US1997/000600 WO1997026883A1 (en) 1996-01-23 1997-01-21 Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Publications (2)

Publication Number Publication Date
NO983372D0 NO983372D0 (no) 1998-07-22
NO983372L true NO983372L (no) 1998-09-21

Family

ID=26712784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983372A NO983372L (no) 1996-01-23 1998-07-22 Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter

Country Status (21)

Country Link
EP (1) EP0879056B1 (pl)
KR (1) KR100298158B1 (pl)
CN (1) CN1190198C (pl)
AT (1) ATE216886T1 (pl)
BR (1) BR9707154A (pl)
CA (1) CA2246162C (pl)
CZ (1) CZ293584B6 (pl)
DE (1) DE69712316T2 (pl)
DK (1) DK0879056T3 (pl)
ES (1) ES2172764T3 (pl)
HU (1) HU220105B (pl)
IL (1) IL125088A0 (pl)
NO (1) NO983372L (pl)
NZ (1) NZ330784A (pl)
PL (1) PL187439B1 (pl)
PT (1) PT879056E (pl)
RU (1) RU2186569C2 (pl)
SI (1) SI9720013A (pl)
SK (1) SK283342B6 (pl)
UA (1) UA46815C2 (pl)
WO (1) WO1997026883A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254911A1 (en) * 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
IL129319A0 (en) 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases
IL144130A0 (en) * 1999-01-29 2002-05-23 Icn Pharmaceuticals Modulation of immune response by ribavirin
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2006218875B2 (en) * 2005-02-25 2012-08-09 Efficas, Inc. Compositions comprising Actinidia and methods of use thereof
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007102081A2 (en) * 2006-03-09 2007-09-13 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5668886A (en) * 1986-03-27 1987-10-20 Harry Edward Gruber A method of increasing adenosine excretion
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
CA2109528A1 (en) * 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
DK0879056T3 (da) 2002-08-19
RU2186569C2 (ru) 2002-08-10
HUP9900681A3 (en) 1999-12-28
EP0879056A1 (en) 1998-11-25
ES2172764T3 (es) 2002-10-01
PT879056E (pt) 2002-10-31
UA46815C2 (uk) 2002-06-17
SK100498A3 (en) 2001-03-12
ATE216886T1 (de) 2002-05-15
DE69712316D1 (en) 2002-06-06
NZ330784A (en) 1999-02-25
DE69712316T2 (de) 2003-01-02
PL187439B1 (pl) 2004-07-30
EP0879056A4 (en) 1999-01-13
NO983372D0 (no) 1998-07-22
HU220105B (hu) 2001-10-28
CZ293584B6 (cs) 2004-06-16
AU1747897A (en) 1997-08-20
HUP9900681A2 (hu) 1999-07-28
AU700642B2 (en) 1999-01-14
CN1209747A (zh) 1999-03-03
KR100298158B1 (ko) 2001-09-06
CZ232998A3 (cs) 1999-04-14
PL328003A1 (en) 1999-01-04
SK283342B6 (sk) 2003-06-03
EP0879056B1 (en) 2002-05-02
SI9720013A (sl) 1999-06-30
IL125088A0 (en) 1999-01-26
CN1190198C (zh) 2005-02-23
CA2246162A1 (en) 1997-07-31
KR19990081930A (ko) 1999-11-15
CA2246162C (en) 2000-04-04
WO1997026883A1 (en) 1997-07-31
BR9707154A (pt) 1999-05-25

Similar Documents

Publication Publication Date Title
NO983372D0 (no) Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter
PT79182A (de) Mittel zur transdermalen applikation von arzneimittelwirkstoffen
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
DE3677897D1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
DE59007178D1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
EP0219076A3 (en) Sustained release composition
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
NO870772D0 (no) Vevplasminogenaktivator for normale humane tykktarmceller.
DE68908117D1 (de) N-acetylglukosamin als zytoprotektives mittel.
IT8548055A1 (it) Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale
ES2098316T3 (es) Procedimiento de purificacion de carrageninas comerciales.
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
ATE79615T1 (de) Cardiotonische phenyloxazolone.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DK369886D0 (da) Hidtil ukendte acylphosphotriamider og pharmaceutisk komposition indeholdende samme til aendring af lipidindholdet i blodplasma hospattedyr
MA21471A1 (fr) Composition de tourrage et son utilisation dans le tourrage et le post-tourrage des peaux animales .
ATE87207T1 (de) Azapropazon zur praevention von post-ischaemischem gewebeschaden.
EP1174141A3 (en) Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
BG102182A (bg) Използване на иприфлавон за намаляване броя на сd8+ клетки
ATE54941T1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application